The role of mitochondria-derived reactive oxygen species in hyperthermia-induced platelet apoptosis

PLoS One. 2013 Sep 4;8(9):e75044. doi: 10.1371/journal.pone.0075044. eCollection 2013.

Abstract

A combination of hyperthermia with radiotherapy and chemotherapy for various solid tumors has been practiced clinically. However, hyperthermic therapy has side effects, such as thrombocytopenia. Up to now, the pathogenesis of hyperthermia-induced thrombocytopenia remains unclear. Previous studies have shown that hyperthermia induces platelet apoptosis. However, the signaling pathways and molecular mechanisms involved in hyperthermia-induced platelet apoptosis have not been determined. Here we show that hyperthermia induced intracellular reactive oxygen species (ROS) production and mitochondrial ROS generation in a time-dependent manner in platelets. The mitochondria-targeted ROS scavenger Mito-TEMPO blocked intracellular ROS and mitochondrial ROS generation. By contrast, inhibitors of reduced nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, nitric oxide synthase, cyclooxygenase and lipoxygenase did not. Furthermore, Mito-TEMPO inhibited hyperthermia-induced malonyldialdehyde production and cardiolipin peroxidation. We also showed that hyperthermia-triggered platelet apoptosis was inhibited by Mito-TEMPO. Furthermore, Mito-TEMPO ameliorated hyperthermia-impaired platelet aggregation and adhesion function. Lastly, hyperthermia decreased platelet manganese superoxide dismutase (MnSOD) protein levels and enzyme activity. These data indicate that mitochondrial ROS play a pivotal role in hyperthermia-induced platelet apoptosis, and decreased of MnSOD activity might, at least partially account for the enhanced ROS levels in hyperthermia-treated platelets. Therefore, determining the role of mitochondrial ROS as contributory factors in platelet apoptosis, is critical in providing a rational design of novel drugs aimed at targeting mitochondrial ROS. Such therapeutic approaches would have potential clinical utility in platelet-associated disorders involving oxidative damage.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Apoptosis* / drug effects
  • Blood Platelets / cytology*
  • Blood Platelets / drug effects
  • Blood Platelets / physiology
  • Cardiolipins / metabolism
  • Humans
  • Hyperthermia, Induced / adverse effects*
  • Lipid Peroxidation / drug effects
  • Malondialdehyde / metabolism
  • Mitochondria / drug effects
  • Mitochondria / enzymology
  • Mitochondria / metabolism*
  • Organophosphorus Compounds / pharmacology
  • Piperidines / pharmacology
  • Reactive Oxygen Species / metabolism*
  • Superoxide Dismutase / metabolism
  • Superoxides / metabolism

Substances

  • Cardiolipins
  • MitoTEMPO
  • Organophosphorus Compounds
  • Piperidines
  • Reactive Oxygen Species
  • Superoxides
  • Malondialdehyde
  • Superoxide Dismutase

Grants and funding

This study was supported by grants from the National Natural Science Foundation of China (NSFC 81270650), the Innovation Program of Shanghai Municipal Education Commission (12YZ068), the Natural Science Foundation of Shanghai (12ZR1429900), the Postdoctoral Science Foundation of Shanghai (12R21411700), the China Postdoctoral Science Foundation (2012M511043). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.